about
Biocompatible dialysis fluids for peritoneal dialysisEffects of ischaemic conditioning on major clinical outcomes in people undergoing invasive procedures: systematic review and meta-analysis.The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis.Effects of climatic region on peritonitis risk, microbiology, treatment, and outcomes: a multicenter registry studyEnd-stage kidney disease due to haemolytic uraemic syndrome--outcomes in 241 consecutive ANZDATA registry cases.The association between peritoneal dialysis modality and peritonitis.The effects of living distantly from peritoneal dialysis units on peritonitis risk, microbiology, treatment and outcomes: a multi-centre registry study.Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.The association between body mass index and mortality in incident dialysis patients.The role of monitoring vancomycin levels in patients with peritoneal dialysis-associated peritonitis.Adherence to guideline recommendations for infection prophylaxis in peritoneal dialysis patientsThe Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modificationsSocio-Economic Status and Peritonitis in Australian Non-Indigenous Peritoneal Dialysis Patients.Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trialRecent peritonitis associates with mortality among patients treated with peritoneal dialysis.Weekend compared with weekday presentations of peritoneal dialysis-associated peritonitis.The outcomes of patients with ESRD and ANCA-associated vasculitis in Australia and New Zealand.Peritoneal phosphate clearance is influenced by peritoneal dialysis modality, independent of peritoneal transport characteristics.The HONEYPOT randomized controlled trial statistical analysis plan.Establishing a clinical trials network in nephrology: experience of the Australasian Kidney Trials Network.The role of monitoring gentamicin levels in patients with gram-negative peritoneal dialysis-associated peritonitis.Is the problem with the vehicle or the destination? Does high-dose ESA or high haemoglobin contribute to poor outcomes in CKD?Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis.Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk.Biocompatible peritoneal dialysis fluids: clinical outcomes.Impact of icodextrin on clinical outcomes in peritoneal dialysis: a systematic review of randomized controlled trials.Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis.A nephrology guide to reading and using systematic reviews of randomized trials.Effect of Fish Oil Supplementation and Aspirin Use on Arteriovenous Fistula Failure in Patients Requiring Hemodialysis: A Randomized Clinical Trial.Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials.OUTCOMES OF CORYNEBACTERIUM PERITONITIS: A MULTICENTER REGISTRY ANALYSIS.Multicenter Registry Analysis of Center Characteristics Associated with Technique Failure in Patients on Incident Peritoneal Dialysis.Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.Association of Socio-Economic Position with Technique Failure and Mortality in Australian Non-Indigenous Peritoneal Dialysis Patients.Breast Cancer and Transplantation.Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients.Duration of Hemodialysis Following Peritoneal Dialysis Cessation in Australia and New Zealand: Proposal for a Standardized Definition of Technique Failure.Center-Specific Factors Associated with Peritonitis Risk-A Multi-Center Registry Analysis.REPRESENTATIVENESS OF HONEYPOT TRIAL PARTICIPANTS TO AUSTRALASIAN PD PATIENTS.End-Stage Kidney Disease Due to Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy - Outcomes in 66 Consecutive ANZDATA Registry Cases.
P50
Q24197836-174DA42E-1836-439B-9440-241F3BDF1A70Q30241704-0C607028-B367-45F0-9E7D-68282F4E5DD7Q30251447-9E41C8B5-4DD6-4663-AE81-CEF8A553519AQ30560814-F19B1934-3D50-4E00-BBFE-3D55FDEAEFC8Q33404656-8F75F0ED-3C48-4961-987D-2A89F4B1A871Q33715831-780E6F04-B08C-49A9-8447-9E19EC5744BDQ34306126-29B051D2-2058-4F91-8DE7-03B2DD9FBEB8Q34534590-8EE8A499-5885-40B3-9431-C20AFAC55D77Q34712804-9D426F3C-0F94-4621-A267-C6C45465D783Q35524820-1094A726-699B-421E-8A55-189539980B36Q35573890-103B9D22-C21D-487F-AF6B-E78A1E7CDBCBQ35676161-B141BC90-C41F-47ED-A378-9F40C616C607Q35904430-D414651F-BF75-4AD9-BD95-4E628678515CQ35961696-34B88FE0-54C6-4F0A-B9B2-3AB39860FC61Q36109181-EC314304-4E94-49E6-B9E0-4AA5DE3B8B8EQ36474262-A4038C9D-9301-435D-A15A-4336A47F2ED5Q36810489-659BF13A-DC83-4CA1-9408-200B1922B772Q36947323-3F8BBAE4-AA05-4DA2-8653-555ACD53841CQ37000708-9902671A-8E0C-47A4-B74F-970CC49F0498Q37503167-5FCD56C6-0823-49B4-B43B-45C774DABEBCQ37669439-45CF4D7F-F2D7-4119-8A68-925979EE83F4Q37832766-71C9BABA-0DE8-43DD-BAA0-2C6FB92E3948Q37925218-12648097-CAAA-4B95-B420-EC76BE24B373Q38009044-880D01CD-0400-45A0-877A-B89360F30868Q38068420-C47F968C-47F6-4DB1-8F2B-45851A495E45Q38089566-D12DFD3E-3B7D-4A8A-8E98-D4F01346B8FDQ38138322-0A4734D1-F1C1-41E8-AC79-1E8C298D1F35Q38222626-6224B468-6408-461D-ADDA-67FB2172F48CQ38382811-83159A8A-9D7A-4AF5-9C2E-94330A45E829Q38545232-5B46462C-080A-4D2A-ACB9-711C737920B2Q38683466-279AFA96-B7F4-4C24-967A-34C267B9D638Q38714996-60DC9F8C-8572-4E7D-B878-0B375A5FA86AQ38941637-157F2FC6-AE6F-4542-BE67-915843C22F14Q38968865-A1283FAD-5D87-480A-95CD-B7F3B54085F2Q39330060-B6DF2A3A-2AAC-42E6-B405-F24262227D99Q39573385-FD70C7FF-544A-46C9-90D0-3ED4A828DBACQ39793472-40E6DEEC-695A-49CC-A542-7E19DC3800E7Q40110472-BB828607-6AE2-4951-8956-FE78F2BFB381Q40416414-681966C1-4612-4013-AC1C-CADAA1BA008DQ40486596-DE81E2A4-32F4-44A8-8AAC-F04401764BE7
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sunil V Badve
@es
Sunil V. Badve
@en
Sunil V. Badve
@nl
Sunil V. Badve
@sl
type
label
Sunil V Badve
@es
Sunil V. Badve
@en
Sunil V. Badve
@nl
Sunil V. Badve
@sl
altLabel
@Badves
@en
prefLabel
Sunil V Badve
@es
Sunil V. Badve
@en
Sunil V. Badve
@nl
Sunil V. Badve
@sl
P1053
F-9049-2010
P106
P1153
7004057316
P1960
nMcRyrEAAAAJ
P21
P31
P3829
P496
0000-0003-2269-312X
P569
2000-01-01T00:00:00Z